Coordinated inhibition of nuclear export and Bcr-Abl1 selectively targets chronic myeloid leukemia stem cells

被引：4

作者：

Than, Hein ^{[1
,2
]}

Pomicter, Anthony D. ^{[1
]}

Yan, Dongqing ^{[1
]}

Beaver, Larry P. ^{[1
]}

Eiring, Anna M. ^{[1
]}

Heaton, William L. ^{[1
]}

Senina, Anna ^{[1
]}

Clair, Phillip M. ^{[1
]}

Shacham, Sharon ^{[3
]}

Mason, Clinton C. ^{[4
]}

O'Hare, Thomas ^{[1
,5
]}

Deininger, Michael W. ^{[1
,5
]}

机构：

[1] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT 84112 USA

[2] Singapore Gen Hosp, Dept Hematol, Singapore, Singapore

[3] Karyopharm Therapeut Inc, Newton, MA USA

[4] Univ Utah, Div Pediat Hematol Oncol, Salt Lake City, UT USA

[5] Univ Utah, Div Hematol & Hematol Malignancies, Salt Lake City, UT 84112 USA

来源：

LEUKEMIA | 2020年 / 34卷 / 06期

基金：

英国医学研究理事会; 美国国家卫生研究院;

关键词：

IMATINIB;

D O I：

10.1038/s41375-020-0708-1

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

[No abstract available]

引用

页码：1679 / 1683

页数：5

共 15 条

[1] Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity [J].

Corbin, Amie S. ;

Agarwal, Anupriya ;

Loriaux, Marc ;

Cortes, Jorge ;

Deininger, Michael W. ;

Druker, Brian J. .

JOURNAL OF CLINICAL INVESTIGATION, 2011, 121 (01) :396-409

[2] KPT-8602, a second-generation inhibitor of XPO1-mediated nuclear export, is well tolerated and highly active against AML blasts and leukemia-initiating cells [J].

Etchin, J. ;

Berezovskaya, A. ;

Conway, A. S. ;

Galinsky, I. A. ;

Stone, R. M. ;

Baloglu, E. ;

Senapedis, W. ;

Landesman, Y. ;

Kauffman, M. ;

Shacham, S. ;

Wang, J. C. Y. ;

Look, A. T. .

LEUKEMIA, 2017, 31 (01) :143-150

[3] Antileukemic activity of nuclear export inhibitors that spare normal hematopoietic cells [J].

Etchin, J. ;

Sun, Q. ;

Kentsis, A. ;

Farmer, A. ;

Zhang, Z. C. ;

Sanda, T. ;

Mansour, M. R. ;

Barcelo, C. ;

McCauley, D. ;

Kauffman, M. ;

Shacham, S. ;

Christie, A. L. ;

Kung, A. L. ;

Rodig, S. J. ;

Chook, Y. M. ;

Look, A. T. .

LEUKEMIA, 2013, 27 (01) :66-74

[4] Transcriptional analysis of quiescent and proliferating CD34+human hemopoietic cells from normal and chronic myeloid leukemia sources [J].

Graham, Susan M. ;

Vass, J. Keith ;

Holyoake, Tessa L. ;

Graham, Gerard J. .

STEM CELLS, 2007, 25 (12) :3111-3120

[5] Genetic and Pharmacologic Inhibition of β-Catenin Targets Imatinib-Resistant Leukemia Stem Cells in CML [J].

Heidel, Florian H. ;

Bullinger, Lars ;

Feng, Zhaohui ;

Wang, Zhu ;

Neff, Tobias A. ;

Stein, Lauren ;

Kalaitzidis, Demetrios ;

Lane, Steve W. ;

Armstrong, Scott A. .

CELL STEM CELL, 2012, 10 (04) :412-424

[6] Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia [J].

Hochhaus, Andreas ;

Larson, Richard A. ;

Guilhot, Francois ;

Radich, Jerald P. ;

Branford, Susan ;

Hughes, Timothy P. ;

Baccarani, Michele ;

Deininger, Michael W. ;

Cervantes, Francisco ;

Fujihara, Satoko ;

Ortmann, Christine-Elke ;

Menssen, Hans D. ;

Kantarjian, Hagop ;

O'Brien, Stephen G. ;

Druker, Brian J. .

NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (10) :917-927

[7] Interferon Consensus Sequence Binding Protein (ICSBP) Decreases β-Catenin Activity in Myeloid Cells by Repressing GAS2 Transcription [J].

Huang, Weiqi ;

Zhou, Wei ;

Saberwal, Gurveen ;

Konieczna, Iwona ;

Horvath, Elizabeth ;

Katsoulidis, Efstratios ;

Platanias, Leonidas C. ;

Eklund, Elizabeth A. .

MOLECULAR AND CELLULAR BIOLOGY, 2010, 30 (19) :4575-4594

[8] shRNA library screening identifies nucleocytoplasmic transport as a mediator of BCR-ABL1 kinase-independent resistance [J].

Khorashad, Jamshid S. ;

Eiring, Anna M. ;

Mason, Clinton C. ;

Gantz, Kevin C. ;

Bowler, Amber D. ;

Redwine, Hannah M. ;

Yu, Fan ;

Kraft, Ira L. ;

Pomicter, Anthony D. ;

Reynolds, Kimberly R. ;

Iovino, Anthony J. ;

Zabriskie, Matthew S. ;

Heaton, William L. ;

Tantravahi, Srinivas K. ;

Kauffman, Michael ;

Shacham, Sharon ;

Chenchik, Alex ;

Bonneau, Kyle ;

Ullman, Katharine S. ;

O'Hare, Thomas ;

Deininger, Michael W. .

BLOOD, 2015, 125 (11) :1772-1781

[9] CD36 defines primitive chronic myeloid leukemia cells less responsive to imatinib but vulnerable to antibody-based therapeutic targeting [J].

Landberg, Niklas ;

von Palffy, Sofia ;

Askmyr, Maria ;

Lilljebjorn, Henrik ;

Sanden, Carl ;

Rissler, Marianne ;

Mustjoki, Satu ;

Hjorth-Hansen, Henrik ;

Richter, Johan ;

Agerstam, Helena ;

Jaras, Marcus ;

Fioretos, Thoas .

HAEMATOLOGICA, 2018, 103 (03) :447-455

[10] A gene expression signature of CD34+ cells to predict major cytogenetic response in chronic-phase chronic myeloid leukemia patients treated with imatinib [J].

McWeeney, Shannon K. ;

Pemberton, Lucy C. ;

Loriaux, Marc M. ;

Vartanian, Kristina ;

Willis, Stephanie G. ;

Yochum, Gregory ;

Wilmot, Beth ;

Turpaz, Yaron ;

Pillai, Raji ;

Druker, Brian J. ;

Snead, Jennifer L. ;

MacPartlin, Mary ;

O'Brien, Stephen G. ;

Melo, Junia V. ;

Lange, Thoralf ;

Harrington, Christina A. ;

Deininger, Michael W. N. .

BLOOD, 2010, 115 (02) :315-325

← 1 2 →